Unknown

Dataset Information

Trends in survival and treatment of SEGA: National Cancer Database Analysis.


ABSTRACT:

Background

SEGA is a rare, slow-growing CNS neoplasm that has historically been treated by surgical resection. However, the advent of a mammalian target of rapamycin complex-1 inhibitor, everolimus, has shown promising results in recent clinical trials. We sought to provide an analysis of epidemiological and survival risk factors in this rare tumor entity, while comparing trends in surgical management before and after introduction of everolimus in SEGAs.

Methods

Patients with SEGA were queried from the National Cancer Database between 2004 and 2015. Standard statistical analysis was conducted to assess variables associated with the odds of performing surgery and survival, while controlling for confounding variables.

Results

A total of 460 patients were diagnosed with

SUBMITTER: Ryoo JS 

PROVIDER: S-EPMC7906259 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature